B3GAT1 Antibody

What is B3GAT1 and what are its primary cellular functions?

B3GAT1 (Beta-1,3-Glucuronyltransferase 1) is a member of the glucuronyltransferase gene family that plays a key role in glycan biosynthesis. It functions as the critical enzyme in glucuronyl transfer reactions during the biosynthesis of the carbohydrate epitope HNK-1 (human natural killer-1, also known as CD57 or LEU7) .

Functionally, B3GAT1:

• Is involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycoproteins

• Plays a role in glycosaminoglycan biosynthesis

• Adds a glucuronic acid (GlcA) residue to terminal sugars

• Has substrates including asialo-orosomucoid (ASOR), asialo-fetuin, and asialo-neural cell adhesion molecule

Importantly, B3GAT1 requires sphingomyelin for optimal activity, with stearoyl-sphingomyelin being most effective, followed by palmitoyl-sphingomyelin and lignoceroyl-sphingomyelin . Activity is demonstrated only with saturated fatty acid sphingomyelins, not unsaturated ones, regardless of acyl group length.

What are the optimal applications for different B3GAT1 antibodies?

Based on validated data, B3GAT1 antibodies have been optimized for multiple applications:

When selecting an antibody, researchers should consider both the application and species reactivity requirements. For instance, if performing immunohistochemistry on paraffin-embedded human tissue, ab199156 has been validated at 1/40 dilution specifically for human thyroid cancer tissue labeling .

What is the expected molecular weight of B3GAT1 and why might it appear at different weights in experimental assays?

The calculated molecular weight of B3GAT1 is approximately 38 kDa, but researchers frequently observe bands at different molecular weights:

• 38 kDa (calculated/theoretical weight)

• ~100-110 kDa (commonly observed in SDS-PAGE)

This discrepancy is attributed to:

• Post-translational modifications, particularly glycosylation, as B3GAT1 is itself a glycosyltransferase

• Possible homodimer formation

• Type II Golgi-resident transmembrane protein structure with specific domains

When conducting Western blot validation, researchers should note that the 66711-1-Ig antibody detects both the 38 kDa and 100 kDa forms in SDS-PAGE analysis, providing flexibility in detecting different states of the protein .

How does B3GAT1 overexpression restrict viral infection, and what experimental approaches can validate this mechanism?

Recent research has identified B3GAT1 as a potent antiviral restriction factor, particularly against influenza viruses. The mechanism has been characterized through comprehensive experimental approaches :

• Mechanistic pathway: B3GAT1 overexpression prevents cell surface sialic acid expression by outcompeting host sialyltransferases, thereby preventing viral binding to sialic acid receptors .

• Experimental validation techniques:

  • CRISPR activation screening using B/Yamagata/16/1988 strain identified B3GAT1 as a viral restriction factor

  • MALDI-TOF mass spectrometry of N-linked glycans showed reduction of sialic acid-containing glycans and increase in glucuronidated glycans in B3GAT1-overexpressing cells

  • Gas chromatography-mass spectrometry (GC-MS) confirmed relatively less Neu5Ac and more GlcA

  • Lectin staining with WGA, MAL I, and SNA demonstrated reduced α2,3- and α2,6-linked sialic acid expression

  • Flow cytometry quantification of fluorescently labeled virions binding to cells confirmed reduced virus binding

• Restriction breadth: B3GAT1 demonstrated broad restriction activity against multiple viruses requiring sialic acid for entry:

  • Victoria and Yamagata lineage IBVs

  • H1N1 and H3N2 IAV strains

  • Enterovirus D68 (EV-D68)

  • Did not affect Coxsackievirus B3 (CVB3) which uses protein receptor for entry

For researchers studying this mechanism, it's important to include appropriate controls, such as overexpression of non-related proteins (e.g., mCherry or GFP) and testing viruses that use non-sialic acid receptors.

What methodological approaches can effectively distinguish between different glycan modifications mediated by B3GAT1?

To accurately characterize B3GAT1-mediated glycan modifications, researchers should employ a multi-method approach:

• Lectin-based profiling:

  • Wheat germ agglutinin (WGA) - broadly binds sialic acids

  • Maackia amurensis lectin I (MAL I) - α2,3-linked sialic acid

  • Sambucus nigra lectin (SNA) - α2,6-linked sialic acid

  • HNK-1 epitope antibody - terminal GlcA sugar

  • Galanthus nivalis lectin (GNL) - mannose sugars

• Mass spectrometry approaches:

  • Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) to identify diverse glycan species

  • Tandem mass spectrometry on per-O-methylated, sialylated, N-linked glycans to distinguish α2,3 vs α2,6 linkages

  • Gas chromatography-mass spectrometry (GC-MS) for monosaccharide composition analysis

• Experimental validation of glycan function:

  • Functional assays showing biological consequences of altered glycosylation

  • Competition assays between B3GAT1 and sialyltransferases

  • Subcellular localization studies within Golgi compartments

These techniques can reveal how B3GAT1 outcompetes sialyltransferases, the extent of glycan modification, and the specific glycan species affected.

What are the critical controls and experimental design considerations when validating B3GAT1 antibody specificity?

When validating B3GAT1 antibody specificity, researchers should implement these critical controls and considerations:

• Genetic controls:

  • B3GAT1 knockout/knockdown cells (negative control)

  • B3GAT1 overexpression systems (positive control)

  • Testing with related family members (B3GAT2, B3GAT3) to confirm specificity

• Sample preparation controls:

  • Include both glycosylated and deglycosylated protein samples, as B3GAT1 shows different molecular weights (38 kDa theoretical vs. 100-110 kDa observed)

  • Test multiple tissue/cell types with known differential expression:

    • Positive samples: lymph node, tonsil, neural tissues, NK cells

    • Cell lines validated: K-562, Jurkat, PC-3, SH-SY5Y, U-251, mouse brain tissue

• Application-specific considerations:

  • For Western blot: Include molecular weight markers and optimize running conditions (10% SDS-PAGE recommended)

  • For IHC-P: Validate on multiple tissue types; thyroid cancer tissue has been validated for ab199156 at 1/40 dilution

  • For ICC/IF: PFA fixation and Triton X-100 permeabilization have been validated with SH-SY5Y cells

  • For flow cytometry: Validated protocols exist for intracellular staining of K-562 cells using 0.40 μg per 10^6 cells

• Epitope mapping information:

  • Consider the immunogen region: ab199156 and ab221756 target different regions (synthetic peptide vs. aa 1-100 recombinant fragment)

  • MAB6698 targets amino acids Asp75-Ile347 of rat B3GAT1

How can researchers effectively study B3GAT1's role in influenza virus restriction in translational models?

Based on recent research demonstrating B3GAT1's antiviral properties, these experimental approaches are recommended for translational studies:

• In vitro cellular models:

  • Generate stable B3GAT1 overexpression in relevant cell types:

    • A549 cells (human lung adenocarcinoma) for initial characterization

    • MDCK cells for virus growth curves

    • NL20 cells (non-tumor human lung cells) for physiologically relevant model

  • Test multiple viruses across MOI ranges (MOI optimization experiments confirmed B3GAT1 restricts infection across all MOIs tested)

• Primary cell and air-liquid interface (ALI) models:

  • Generate ALI cultures from murine tracheas to model differentiated respiratory epithelium

  • Validate differentiation status by staining for ciliated cells

  • Deliver human B3GAT1 using serotype 6 adeno-associated viral (AAV6) gene transfer vectors

  • Quantify B3GAT1 expression by qPCR (expected ~10,000-fold increase compared to controls)

  • Assess infection with multiple influenza strains and measure viral titers

• In vivo models:

  • Express B3GAT1 specifically in murine respiratory epithelium

  • Challenge with lethal doses of various influenza viruses, including:

    • Yamagata/Victoria-lineage IBVs

    • H1N1/H3N2 IAVs

    • Pandemic-like H1N1 IAV

  • Monitor survival, weight loss, and viral loads in respiratory tissues

• Methodological controls:

  • Include GFP or mCherry-expressing controls

  • Test both related viruses (different influenza strains) and unrelated viruses (EV-D68, CVB3)

  • Assess potential toxicity/side effects of B3GAT1 overexpression in respiratory tissues

This multilevel approach allows for comprehensive assessment of B3GAT1's antiviral potential from cell culture to animal models, providing robust translational evidence.

What optimization strategies should be employed when using B3GAT1 antibodies for Western blot analysis?

For optimal Western blot results with B3GAT1 antibodies, researchers should consider these technical recommendations:

• Sample preparation:

  • Use appropriate lysis buffers that preserve glycosylated proteins

  • Consider testing both reduced and non-reduced conditions, as protein dimerization may affect epitope accessibility

  • Include both low molecular weight (~38 kDa) and high molecular weight (~100-110 kDa) markers

• Gel selection and running conditions:

  • Use 10% SDS-PAGE gels for optimal separation of B3GAT1

  • Consider gradient gels (4-12%) if detecting both 38 kDa and 100 kDa forms simultaneously

  • Adjust running time to properly resolve the higher molecular weight band

• Antibody-specific dilutions:

  • ab199156: Follow manufacturer's recommended dilution

  • 66711-1-Ig: Use at 1:2000-1:16000 dilution for optimal results

  • NK1/7566: Use at 1-2 μg/ml concentration

• Positive controls:

  • K-562 cells, mouse brain tissue, Jurkat cells, PC-3 cells, SH-SY5Y cells, and U-251 cells have all been validated as positive samples

  • Consider using B3GAT1-overexpressing cell lysates as strong positive controls

• Troubleshooting inconsistent results:

  • If detecting only the low or high molecular weight form, adjust exposure time

  • Consider stripping and reprobing with a different B3GAT1 antibody that targets a different epitope

  • For inconsistent glycosylation patterns, consider enzymatic deglycosylation to confirm protein identity

How should researchers design experiments to study the interaction between B3GAT1 and sphingomyelin in enzymatic activity assays?

To effectively study B3GAT1-sphingomyelin interactions, which are critical for enzymatic activity, researchers should employ these methodological approaches:

• Sphingomyelin dependency testing:

  • Assay B3GAT1 activity with different sphingomyelin species:

    • Stearoyl-sphingomyelin (most effective)

    • Palmitoyl-sphingomyelin (intermediate effectiveness)

    • Lignoceroyl-sphingomyelin (less effective)

    • Unsaturated fatty acid sphingomyelins (negative control - should show no activity)

  • Establish dose-response curves for each sphingomyelin species

• Substrate selection:

  • Include validated B3GAT1 substrates:

    • Asialo-orosomucoid (ASOR)

    • Asialo-fetuin

    • Asialo-neural cell adhesion molecule

  • Consider testing both natural and synthetic acceptors

• Activity assay methodology:

  • Employ a phosphatase-coupled method for assaying enzyme activity

  • Monitor glucuronic acid transfer to acceptor substrates

  • Include appropriate positive and negative controls

• Sphingomyelin-B3GAT1 binding studies:

  • Perform co-immunoprecipitation assays to detect physical interactions

  • Use surface plasmon resonance to quantify binding affinities

  • Conduct mutagenesis studies to identify critical residues for sphingomyelin interaction

• Cellular localization experiments:

  • Perform co-localization studies of B3GAT1 and sphingomyelin in Golgi compartments

  • Use fluorescently labeled sphingomyelins to track interaction in live cells

  • Assess how sphingomyelin depletion affects B3GAT1 Golgi localization

These approaches provide comprehensive assessment of the critical relationship between B3GAT1 and sphingomyelin that governs enzymatic activity.

How can B3GAT1's antiviral properties be therapeutically exploited, and what experimental approaches would validate this potential?

Recent discovery of B3GAT1 as a broad-spectrum antiviral restriction factor opens possibilities for therapeutic development. Researchers should consider these experimental approaches:

This research direction represents a host-directed antiviral strategy with significant translational potential for respiratory virus prevention .

What is the relationship between B3GAT1 expression and natural killer cell function in immunological contexts?

As B3GAT1 (previously known as CD57) marks natural killer (NK) cells and has roles in glycosylation, understanding its immunological functions requires systematic investigation:

• NK cell subset characterization:

  • Flow cytometric analysis of B3GAT1/CD57 expression across NK cell subpopulations

  • Correlation with NK cell maturation, cytotoxicity, and cytokine production

  • Analysis of B3GAT1 co-expression with other NK cell markers (CD16, CD56, KIRs)

• Functional implications of B3GAT1 in NK cells:

  • Compare cytolytic activity between B3GAT1+ and B3GAT1- NK cells

  • Assess impact of B3GAT1 knockout/knockdown on NK cell function

  • Evaluate proliferative capacity and survival of B3GAT1+ NK subsets

• Glycan-dependent NK cell recognition mechanisms:

  • Investigate how B3GAT1-mediated glycan modifications affect:

    • NK cell receptor-ligand interactions

    • NK cell trafficking and tissue localization

    • NK cell-target cell synapse formation

• Clinical correlations:

  • Analysis of B3GAT1+ NK cells in various disease contexts:

    • Viral infections (particularly influenza)

    • Cancer immunosurveillance (B3GAT1+ NK cells in follicular lymphomas)

    • Chronic NK-cell lymphocytosis

    • Autoimmune disorders

• Experimental validation approaches:

  • Use NK1/7566 B3GAT1 antibody (validated for human lymph node/tonsil) for IHC-P studies

  • Flow cytometric analysis with intracellular staining using 66711-1-Ig antibody

  • Functional assays following B3GAT1 genetic manipulation